Michel Farnier hechos.

Jennifer G hechos . Robinson, M.D., M.P.H., Michel Farnier, M.D., Ph.D., Michel Krempf, M.D., Jean Bergeron, M.D.D., Maurizio Averna, M.D., Erik S. Stroes, M.D., Ph.D., Gisle Langslet, M.D., Frederick J. Raal, M.D., Ph.D., Mahfouz El Shahawy, M.D., Michael J. Koren, M.D., Norman E. Lepor, M.D., Christelle Lorenzato, M.Sc., Robert Pordy, M.D., Umesh Chaudhari, M.D., and John J.P. Kastelein, M.D., Ph.D. In stage 2 studies long lasting 8 to 12 weeks, the PCSK9 inhibitor alirocumab lowered LDL cholesterol amounts by 40 to 70 percent when put into background statin therapy.1-3 However, this fresh treatment needs to be evaluated in bigger populations for longer intervals of follow-up to determine its safety and efficacy.4-7 We conducted a 78-week trial comparing alirocumab with placebo in 2341 patients at risky for cardiovascular occasions who have been receiving treatment with statins at the utmost tolerated dose , with or without additional lipid-lowering therapy.